Please try another search
For the three months ended 31 March 2015, CFR Pharmaceuticals SA revenues increased 8% to $195.2M. Net income decreased 30% to $21M. Revenues reflect Specialty Pharma segment increase of 13% to $126.6M, Other segment increase of 44% to $14.5M, Venezuela segment increase of 66% to $36.7M, Chile segment increase of 11% to $39.2M. Net income was offset by Distribution Cost increase of 12% to $6.4M (expense).
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 195.23 | 181.55 | 180.64 | 190.06 |
Gross Profit | 139.87 | 126 | 112.74 | 138.21 |
Operating Income | 55.94 | -19.71 | -81.92 | 35.27 |
Net Income | 20.99 | -47.68 | -88.42 | 20.23 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 1140.31 | 1126.56 | 1208.35 | 1366.25 |
Total Liabilities | 813.76 | 770.34 | 723.3 | 750.28 |
Total Equity | 326.55 | 356.22 | 485.05 | 615.97 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 24.12 | 17.66 | 2.78 | 30.74 |
Cash From Investing Activities | -3.57 | 3.96 | 30.24 | 38.4 |
Cash From Financing Activities | 13.02 | 41.44 | -12.27 | -15.62 |
Net Change in Cash | 30.2 | 54.87 | 14.59 | 49.59 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review